Cargando…

Understanding and Improving (18)F-Fluciclovine PET/CT Reports: A Guide for Physicians Treating Patients with Biochemical Recurrence of Prostate Cancer

The positron emission tomography (PET) tracer (18)F-fluciclovine has seen increasing use to localize disease in men with biochemical recurrence of prostate cancer, i.e., elevated prostate-specific antigen (PSA) levels post-treatment. (18)F-Fluciclovine PET/computed tomography (CT) imaging reports no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lowentritt, Benjamin H., Kipper, Michael S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199579/ https://www.ncbi.nlm.nih.gov/pubmed/32395349 http://dx.doi.org/10.1155/2020/1929565

Ejemplares similares

Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer
por: Farkas, Amy B., et al.
Publicado: (2021)

(18)F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review
por: Rais-Bahrami, Soroush, et al.
Publicado: (2021)

Texture Analysis of F-18 Fluciclovine PET/CT to Predict Biochemically Recurrent Prostate Cancer: Initial Results
por: Kang, Hakmook, et al.
Publicado: (2020)

Detection of Recurrent Prostate Cancer With (18)F-Fluciclovine PET/MRI
por: Selnæs, Kirsten Margrete, et al.
Publicado: (2020)

The Diagnostic Role of (18)F-Choline, (18)F-Fluciclovine and (18)F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis
por: Wang, Rang, et al.
Publicado: (2021)

[(18)F]Fluciclovine PET/CT Improves the Clinical Management of Early Recurrence Prostate Cancer Patients
por: Nappi, Anna Giulia, et al.
Publicado: (2022)

F-18 Fluciclovine PET-CT Findings and Pseudoprogression on Immunotherapy
por: Poindexter, Bradley C, et al.
Publicado: (2022)

(18)F-Fluciclovine ((18)F-FACBC) PET imaging of recurrent brain tumors
por: Michaud, Laure, et al.
Publicado: (2019)

Impact of (18)F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy
por: Payne, Heather, et al.
Publicado: (2021)

(18)F-Fluciclovine–Avid Axillary Lymph Nodes After COVID-19 Vaccination on PET/CT for Suspected Recurrence of Prostate Cancer
por: Peacock, Justin G., et al.
Publicado: (2022)

Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer
por: Bach-Gansmo, Tore, et al.
Publicado: (2022)

Comparison of [(18)F]fluciclovine and [(18)F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients
por: Stokke, Caroline, et al.
Publicado: (2022)

Cost–consequence analysis of (18)F-fluciclovine for the staging of recurrent prostate cancer
por: Jensen, Ivar S, et al.
Publicado: (2020)

[(18)F]-Fluciclovine PET discrimination of recurrent intracranial metastatic disease from radiation necrosis
por: Parent, Ephraim E., et al.
Publicado: (2020)

The Role of [(18)F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [(11)C]Choline PET/CT and Histopathological Analysis
por: Zanoni, Lucia, et al.
Publicado: (2021)

Characterising (18)F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging
por: Scott, N. P., et al.
Publicado: (2021)

Exploratory Analysis of Serial (18)F-fluciclovine PET-CT and Multiparametric MRI during Chemoradiation for Glioblastoma
por: Fatania, Kavi, et al.
Publicado: (2022)

Prediction of prostate cancer aggressiveness using (18)F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI
por: Movahedi, Parisa, et al.
Publicado: (2020)

[(18)F]Fluciclovine PET discrimination between high- and low-grade gliomas
por: Parent, Ephraim E., et al.
Publicado: (2018)

(18)F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling
por: Henderson, Fraser, et al.
Publicado: (2020)

Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation
por: Teoh, Eugene J, et al.
Publicado: (2018)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

The utility of [(18)F]Fluciclovine PET/CT in Evaluating Nonmetastatic Castrate-Resistant Prostate Cancer Patients (nmCRPCp): diagnostic performance and impact on management
por: Soliman, Moataz, et al.
Publicado: (2023)

[(18)F]fluciclovine vs. [(18)F]fluorocholine Positron Emission Tomography/Computed Tomography: A Head-to-Head Comparison for Early Detection of Biochemical Recurrence in Prostate Cancer Patients
por: Ferrari, Cristina, et al.
Publicado: (2022)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Fluciclovine positron emission tomography in the setting of biochemical recurrence following local therapy of prostate cancer
por: Glaser, Zachary A., et al.
Publicado: (2018)

18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy
por: Malviya, Gaurav, et al.
Publicado: (2020)

Early lesion detection with (18)F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer
por: Wondergem, M., et al.
Publicado: (2019)

A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
por: Rousseau, Etienne, et al.
Publicado: (2019)

Evaluation of (18)F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
por: Zhou, Xing, et al.
Publicado: (2021)

BIMG-12. [18F]FLUCICLOVINE PET TO DISTINGUISH PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN POST-TREATMENT GLIOBLASTOMA
por: Nabavizadeh, Ali, et al.
Publicado: (2021)

Glioblastoma PET/MRI: kinetic investigation of [(18)F]rhPSMA-7.3, [(18)F]FET and [(18)F]fluciclovine in an orthotopic mouse model of cancer
por: Lindemann, Marcel, et al.
Publicado: (2022)

Simultaneous (18)F-fluciclovine Positron Emission Tomography and Magnetic Resonance Spectroscopic Imaging of Prostate Cancer
por: Esmaeili, Morteza, et al.
Publicado: (2018)

[(18)F]DCFPyL PET/CT versus [(18)F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study
por: Oprea-Lager, Daniela-Elena, et al.
Publicado: (2023)

NEIM-02 CHARACTERIZATION OF LARGE BRAIN METASTASES WITH(18)F-FLUCICLOVINE PET/CT TREATED WITH STAGED STEREOTACTIC RADIOSURGERY (SSRS): INTERIM ANALYSIS OF A PILOT STUDY
por: Rosa, Alonso La, et al.
Publicado: (2023)

[(18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer
por: Pasqualetti, Francesco, et al.
Publicado: (2019)

In Molecular Pursuit of Bone Metastasis by Fluciclovine PET
por: Lindenberg, Liza
Publicado: (2017)

Head-to-Head Comparison of [(18)F]F-choline and Imaging of Prostate-Specific Membrane Antigen, Using [(18)F]DCFPyL PET/CT, in Patients with Biochemical Recurrence of Prostate Cancer
por: García-Zoghby, Laura, et al.
Publicado: (2023)

18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis
por: Biscontini, Giuseppina, et al.
Publicado: (2021)

Imaging Glioblastoma With (18)F-Fluciclovine Amino Acid Positron Emission Tomography
por: Scarpelli, Matthew L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fm73qtju2lsarmsos0bpb1vfd7